• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Apollomics Inc. - Class A Ordinary Shares (NQ: APLM )

    0.1460 +0.0038 (+2.67%)
    Streaming Delayed Price Updated: 3:59 PM EDT, Oct 1, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 1,200,939
    Open 0.1422
    Bid (Size) 0.1425 (25)
    Ask (Size) 0.1460 (24)
    Prev. Close 0.1422
    Today's Range 0.1360 - 0.1580
    52wk Range 0.1053 - 3.710
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    12 Health Care Stocks Moving In Monday's After-Market Session
    Via Benzinga
    Apollomics Presents Vebreltinib Data in Patients with Non-Small Cell Lung Cancer with METex14 Skipping Mutations at European Society for Medical Oncology (ESMO) Congress 2024
    Vebreltinib is efficacious in both treatment naïve and previously treated patients with NSCLC with METex14 skipping, and regardless of co-occurring MET amplification 
    From Apollomics Inc.
    Via GlobeNewswire

    Performance

    YTD
    -84.12%
    -84.12%
    1 Month
    +29.20%
    +29.20%
    3 Month
    -30.48%
    -30.48%
    6 Month
    -80.00%
    -80.00%
    1 Year
    -95.94%
    -95.94%

    More News

    Read More
    Apollomics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
    From Apollomics Inc.
    Via GlobeNewswire
    What's Going On With Apollomics (APLM) Stock Exploding Higher?
    Via Benzinga
    Apollomics Reports First Half 2024 Financial Results and Highlights Vebreltinib Clinical Progress
    From Apollomics Inc.
    Via GlobeNewswire
    S&P 500 Gains 1%; Home Depot Earnings Top Views
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Why Is Penny Stock Apollomics Trading Higher On Tuesday?
    Via Benzinga
    Nasdaq Surges 200 Points; US Producer Prices Increase 0.1% In July
    Via Benzinga
    Apollomics Announces Positive Preliminary Data of Vebreltinib in Patients with Non-CNS MET Fusion Solid Tumors from its Phase 2 SPARTA Trial
    From Apollomics Inc.
    Via GlobeNewswire
    Apollomics to Present at the Canaccord Genuity 44th Annual Growth Conference
    From Apollomics Inc.
    Via GlobeNewswire
    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
    Via InvestorPlace
    Why Chuy's Holdings Shares Are Trading Higher By 47%; Here Are 20 Stocks Moving Premarket
    Via Benzinga
    Apollomics Granted 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Price Requirement
    From Apollomics Inc.
    Via GlobeNewswire
    Apollomics Announces Updated Strategic Focus and Leadership Team Changes
    From Apollomics Inc.
    Via GlobeNewswire
    Apollomics Announces Vebreltinib Data at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
    From Apollomics Inc.
    Via GlobeNewswire
    12 Health Care Stocks Moving In Wednesday's Intraday Session
    Via Benzinga
    Apollomics Announces Presentation at the 2024 BIO International Convention
    From Apollomics Inc.
    Via GlobeNewswire
    Apollomics Announces Private Placement Financing and Addition to Board of Directors
    From Apollomics Inc.
    Via GlobeNewswire
    Apollomics Announces Approval of Vebreltinib in China as a First-in-Class Treatment for Gliomas with MET Fusion Gene
    From Apollomics Inc.
    Via GlobeNewswire
    Apollomics Presents Vebreltinib Data at the 2024 American Association for Cancer Research (AACR) Annual Meeting
    From Apollomics Inc.
    Via GlobeNewswire
    Apollomics Announces Poster Presentations of Vebreltinib Data at the 2024 American Association for Cancer Research (AACR) Annual Meeting
    From Apollomics Inc.
    Via GlobeNewswire
    12 Health Care Stocks Moving In Monday's After-Market Session
    Via Benzinga
    Apollomics Highlights Clinical Progress and Reports Full Year 2023 Financial Results
    From Apollomics Inc.
    Via GlobeNewswire
    12 Health Care Stocks Moving In Tuesday's After-Market Session
    Via Benzinga
    Apollomics to Announce Full Year 2023 Financial Results and Host Conference Call on March 28, 2024
    From Apollomics Inc.
    Via GlobeNewswire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.